Guardant Health’s (NASDAQ:GH) Q3 2026 sales beat estimates but stock drops 10.2%
Guardant Health reported Q3 2026 revenue of $361M, beating estimates by 2.9% and growing 36.1% YoY. Adjusted EPS of -$0.29 also beat estimates. The company raised full-year revenue guidance to $1.37B. Despite positive results, the stock dropped 10.2%.
How this was made
The 30-second read
Why it matters
The earnings beat was offset by a 10.2% share decline, reflecting market concerns over margins and future growth.
Market read
First-report earnings with guidance raise; significant for biotech sector and growth-oriented investors.
What to watch
Improved free cash flow trajectory and margin expansion potential may support longer-term upside
Background
Guardant Health reported Q3 2026 earnings, beating consensus on revenue and EPS, and lifted its full-year revenue outlook.
Ticker impact
Q3 2026 results beat revenue and EPS estimates and raised full-year revenue guidance
likely pressure as the market prices in the guidance raise despite the beat
The surprise drop suggests investors are skeptical of the guidance and margin outlook
Market effects
May weigh on other liquid biopsy and biotech stocks as guidance expectations tighten
U.S. biotech sector could see modest pullback in pre-market trading
Limited to investors focused on U.S. healthcare and precision oncology
Counterpoint
The beat and raised guidance could be a buying opportunity if the sell-off is overblown
Key entities
- CompanyGuardant Health
U.S.-listed liquid biopsy firm (NASDAQ:GH) reporting Q3 2026 results
